SCORED Trial (Sotagliflozin) Risk Index Calculator

SCORED Trial (Sotagliflozin) Risk Index — explanation and clinical context This calculator implements a trial-derived risk estimator based on SCORED trial aggregate results. SCORED enrolled adults with type 2 diabetes and chronic kidney disease and reported a primary composite event rate in the placebo arm of approximately 7.5 events per 100 patient-years (≈7.5% per year) and an estimated hazard ratio of 0.74 for the sotagliflozin arm versus placebo for the primary composite endpoint; the default values in this tool reflect these trial-level numbers. By default the tool uses the trial average baseline risk (7.5%/year) or you may supply your own estimated baseline annual risk (%) to reflect a different patient or population.

The treated-event estimate is calculated assuming a constant proportional hazard (treated risk = baseline risk × HR). Clinical interpretation: this tool provides an estimate of absolute and relative treatment effect for a one-year horizon using SCORED trial HRs. It is not a validated individualized prediction model; personalized risk depends on many patient-level factors not captured here.

Use these estimates as transparent, trial-based approximations to inform discussions about expected absolute benefit and NNT when considering sotagliflozin in populations similar to SCORED participants.